Similarly, anti-PD1 monotherapy reduced the Ki67-positive population to 51.97 ± 1.39%, and the combination of XUC with anti-PD1 resulted in the most pronounced reduction, with only 24.73 ± 8.62% of tumor cells expressing Ki67 (Figure 2B). The gene discussed is MKI67; the disease is neoplasm.